Bill revision could mean money for NJ drug company
(AP) -- A billion-dollar "technical revision" added to a patent bill passed by the House last week could provide huge financial benefits to one pharmaceutical company and a law firm.
Jun 30, 2011
5 / 5 (1)
0
